Fold Increase in PBPC Levels From Baseline to day 15 After Chemotherapy for Placebo and PEG-rHuMGDF
| . | Placebo + Filgrastim (n = 10) . | PEG-rHuMGDF* + Filgrastim (n = 25) . | P4-151 . |
|---|---|---|---|
| GM-CFC | 3 (2-46) | 191 (61-2,358) | .002 |
| Meg-CFC | 5 (2-272) | 247 (36-1,352) | .07 |
| BFU-E | 2 (1-25) | 64 (18-430) | .004 |
| CD34+ cells | 1 (0.7-6) | 20 (4-69) | .03 |
| . | Placebo + Filgrastim (n = 10) . | PEG-rHuMGDF* + Filgrastim (n = 25) . | P4-151 . |
|---|---|---|---|
| GM-CFC | 3 (2-46) | 191 (61-2,358) | .002 |
| Meg-CFC | 5 (2-272) | 247 (36-1,352) | .07 |
| BFU-E | 2 (1-25) | 64 (18-430) | .004 |
| CD34+ cells | 1 (0.7-6) | 20 (4-69) | .03 |
PBPC levels are median (interquartile range).
Abbreviations: GM-CFC, granulocyte-macrophage colony-forming cells; Meg-CFC, megakaryocyte colony-forming cells; BFU-E, erythroid burst-forming units.
Combined fold increase for all patients administered doses of PEG-rHuMGDF of 0.3, 1.0, 3.0, or 5.0 μg/kg. Doses of PEG-rHuMGDF of 0.03 and 0.1 μg/kg did not enhance mobilization of PBPC compared with placebo plus filgrastim.
P values calculated using the rank sum test.